Better Health for All

Adaptimmune's core product, TECELRA, is an FDA-approved, first-in-class engineered cell therapy for synovial sarcoma, a solid tumor with a 20% five-year survival rate for metastatic cases.

It is the first new therapy option in over a decade for this cancer. , demonstrating an overall response rate of 43% and a complete response rate of 4.5% in trials. The company's business model is exclusively focused on developing cancer immunotherapies, with no revenue from harmful products. In the first quarter of 2025, Adaptimmune reported nearly $29 million in research and development spending, significantly exceeding its product revenue of just over $4 million, indicating 100% R&D investment in health improvement. However, TECELRA carries a Boxed Warning for Cytokine Release Syndrome (CRS), which occurred in 75% of patients (2% Grade ≥3), and other common adverse reactions such as infections (32%, 14% Grade 3) and cytopenia. The company provides comprehensive risk disclosures for TECELRA, including the Boxed Warning and detailed information on adverse reactions. The company is exclusively focused on treatment, with no stated emphasis on disease prevention. While Adaptimmune establishes Authorized Treatment Centers and provides an AdaptimmuneAssist Order Portal for healthcare providers, it also plans to cut its remaining workforce by 62% after a deal, following a 29% headcount reduction earlier in the year. The listed price for TECELRA is $727,000.

Fair Money & Economic Opportunity

Adaptimmune Therapeutics plc is a biopharmaceutical company focused on cancer immunotherapies, not a financial institution. The company's core business does not involve lending, insuring, moving, or storing money, which is the focus of the 'Fair Money & Economic Opportunity' value. The AdaptimmuneAssist program offers patient support, including travel, copay, and financial assistance for TECELRA treatment, which pertains to healthcare costs rather than financial services or products.

Therefore, the KPIs designed for financial institutions are not applicable to Adaptimmune.

Fair Pay & Worker Respect

No data relevant to Fair Pay & Worker Respect metrics, such as living wage coverage, CEO to median pay ratio, collective bargaining, safety incident rates, pay equity, worker engagement, turnover rates, labor violations, insecure contracts, or health insurance coverage, could be extracted from the provided articles. The Glassdoor review page was inaccessible

, and the company's website article focused on its cell therapy platform , containing no relevant information.

Fair Trade & Ethical Sourcing

Adaptimmune explicitly prohibits child labor, forced labor, and human trafficking in its operations, stating it does not condone or employ such practices and will not tolerate exploitation.

The company will not employ anyone under the age of sixteen, even if local law permits. It also commits to not conducting business with third parties, agents, or suppliers who engage in these practices. Adaptimmune screens its counterparties against sanctioned lists and to identify beneficial owners to prevent involvement in financial crime. Supplier contracts include clauses requiring compliance with anti-slavery and human rights legislation, prohibiting child labor, and mandating adherence to anti-bribery and anti-corruption laws. No substantiated forced or child labor incidents have been reported in the last three years. The company reserves the right to inspect supplier facilities and processes within 30 days of a request.

Honest & Fair Business

Adaptimmune's Board of Directors consists of 9 members

, with 8 (88.89%) qualifying as independent . The company commits to addressing good-faith disputes of invoices within 30 days of receipt. An anti-corruption policy is in place, complying with the US Foreign Corrupt Practices Act and the UK Bribery Act 2010 , and explicitly prohibits bribery and facilitation payments ; however, information on training frequency or effectiveness metrics is not provided. A whistleblower policy offers anonymous online, phone, and postal reporting channels for ethical misconduct and strictly prohibits retaliation against employees who report violations in good faith , but there is no evidence of independent investigation processes for these reports.

Kind to Animals

Adaptimmune Therapeutics plc uses animal testing for its drugs and is included on the Cruelty Free Investing 'use of animals' list.

The company conducts both in vitro and animal studies for preclinical testing, with animal studies being a part of their development process. While preclinical trials must comply with the U.S. Department of Agriculture's Animal Welfare Act, no explicit internal animal testing policy is stated.

Planet-Friendly Business

Adaptimmune's estimated Scope 1 greenhouse gas emissions were 0.00 tCO2-e for both 2022 and 2023.

Estimated Scope 2 emissions were 1,264.66 tCO2-e in 2023, an increase from 892.84 tCO2-e in 2022. The total estimated greenhouse gas emissions (Scope 1 and 2) were 1,264.66 tCO2-e in 2023. The company is considered a "low energy user" and is exempt from detailed energy reporting. It has a recycling program in its offices and encourages remote working, online conferencing, and bike-to-work schemes to minimize indirect emissions and business travel. No environmental compliance violations were reported. However, Adaptimmune has not mentioned Science Based Targets initiative (SBTi) or aligned targets, nor has it declared a net-zero target year. There is no specific data on the percentage of renewable energy used, water usage per revenue, green building certifications for its facilities, or a quantitative waste diversion rate. The company also lacks data on EU Taxonomy alignment for capital expenditure, lifecycle impact analysis for products, recycled to virgin material ratios, or carbon offset quality. Furthermore, there is no specific data on supply chain climate transparency, supplier SBTi targets, biodiversity efforts, deforestation policy, environmental impact assessments, TCFD alignment, climate scenario analysis, water sourcing from stressed basins, packaging CO2 reduction, climate justice initiatives, just transition programs, or climate adaptation financing.

Respect for Cultures & Communities

The provided articles do not contain specific information regarding Adaptimmune Therapeutics plc's engagement with cultures and communities. There is a lack of specific data on community engagement, cultural impact assessments, and social license to operate.

No information is available on formal partnerships with indigenous or local community groups, revenue reinvested in local community development, cultural appropriation incidents, local employment ratios, grievance mechanisms, community complaint resolution times, FPIC participation rates, community governance inclusion, cultural preservation investments, local procurement share, indigenous supplier engagement, cultural site protection, charitable giving to cultural heritage organizations, community fund allocation, language inclusivity, cultural incident response, or cultural sensitivity training completion.

Safe & Smart Tech

Adaptimmune states it complies with the EU General Data Protection Regulation (GDPR), the California Consumer Privacy Act (CCPA), SEC legislation and regulations, and all other applicable data protection and privacy laws.

The company has a Privacy Officer and acknowledges users' right to complain to the Information Commissioner’s Office (ICO) in the UK. Users are afforded comprehensive rights to access, correct, erase, object to, restrict, and transfer their personal data, and to withdraw consent, with the company aiming to respond within one month. No documented data breaches or incidents of unauthorized data use have been reported. The company implements processes to regularly assess, manage, and identify potential cybersecurity risks, utilizing security tools for timely incident investigation. It also has procedures for notifying and remediating data security incidents, and employs encryption methods for transferring confidential information. Staff receive training on cybersecurity safeguards and threat identification. The company uses Cyber EssentialsTM or equivalent information risk/cybersecurity policies and collaborates with third parties to assess cybersecurity prevention and response systems. Adaptimmune collects personal data including name, contact data, and website usage information.